Trial status: Open

Treatment type: Surgical

Stage of Disease: Advanced

Intent of Treatment: Recurrence prevention

Title: A phase III multicenter randomized trial of sentinel lymphadenectomy and complete lymph node dissection versus sentinel lymphadenectomy alone in cutaneous melanoma patients with molecular or histopathological evidence of metastases in the sentinel node.

Lay Summary: New research indicates that by histopathological and molecular techniques, approximately 70-80% of melanoma patients with micrometastases in the sentinel nodes (SNs) have no other involved nodes. A complete lymph node dissection may not be necessary in these patients because sentinel lymphadenectomy may have already removed all the nodes containing tumor metastases. 

The Multicentre Selective Lymphadenectomy Trial 2 is designed to determine whether melanoma-specific survival associated with intra-operative lymphatic mapping and sentinel lymphadenectomy alone, is equivalent to melanoma-specific survival associated with lymphatic mapping, sentinel lymphadenectomy and complete lymph node dissection, in patients with sentinel node metastases detected by histopathologic or molecular techniques.

Contacts